Neuropeptides in eating disorders.
The past decade has witnessed a dramatic acceleration in research on the role of the neuropeptides in the regulation of eating behavior and body weight homeostasis. This expanding research focus has been driven in part by increasing public health concerns related to obesity and the eating disorders anorexia nervosa (AN) and bulimia nervosa (BN). Preclinical advances have been facilitated by the development of new molecular and behavioral research methodologies. With a focus on clinical investigations in AN and BN, this article reviews research on selected hypothalamic and gut-related peptide systems with prominent effects on eating behavior. Studies of the orexigenic peptides neuropeptide Y and the opioid peptides have shown state-related abnormalities in patients with eating disorders. With respect to gut-related peptides, there appears to be substantial evidence for blunting in the meal-related release of the satiety promoting peptide cholecystokinin in BN. Fasting plasma levels of the orexigenic peptide ghrelin have been found to be elevated in patients with AN. As discussed in this review, additional studies will be needed to assess the role of nutritional and body weight changes in neuropeptide alterations observed in symptomatic eating disorder patients, and to identify stable trait-related abnormalities in neuropeptide regulation that persist in individuals who have recovered from an eating disorder.
Jimerson
David C
DC
Department of Psychiatry, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA.
Wolfe
Barbara E
BE
D000856:Anorexia Nervosa / Q000503:physiopathology*; D002032:Bulimia / Q000503:physiopathology*; D002766:Cholecystokinin / Q000097:blood; D006801:Humans; D007031:Hypothalamus / Q000503:physiopathology; D009434:Neural Pathways / Q000503:physiopathology; D009479:Neuropeptides / Q000502:physiology*; D012528:Satiety Response / Q000502:physiology
D009479:Neuropeptides; D002766:Cholecystokinin